CN105063186A - 用于治疗、诊断和监测阿尔茨海默病的方法 - Google Patents

用于治疗、诊断和监测阿尔茨海默病的方法 Download PDF

Info

Publication number
CN105063186A
CN105063186A CN201510445488.3A CN201510445488A CN105063186A CN 105063186 A CN105063186 A CN 105063186A CN 201510445488 A CN201510445488 A CN 201510445488A CN 105063186 A CN105063186 A CN 105063186A
Authority
CN
China
Prior art keywords
application
experimenter
snp
amino
unc5c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510445488.3A
Other languages
English (en)
Chinese (zh)
Inventor
蒂莫西·W·贝伦斯
罗伯特·R·格雷厄姆
图沙尔·班加莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN105063186A publication Critical patent/CN105063186A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
CN201510445488.3A 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法 Pending CN105063186A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558197P 2011-11-10 2011-11-10
US61/558,197 2011-11-10
US201261671531P 2012-07-13 2012-07-13
US61/671,531 2012-07-13
CN201280055180.2A CN103930568A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280055180.2A Division CN103930568A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN105063186A true CN105063186A (zh) 2015-11-18

Family

ID=47222323

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610369743.5A Pending CN106011243A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法
CN201510445488.3A Pending CN105063186A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法
CN201280055180.2A Pending CN103930568A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610369743.5A Pending CN106011243A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280055180.2A Pending CN103930568A (zh) 2011-11-10 2012-11-09 用于治疗、诊断和监测阿尔茨海默病的方法

Country Status (12)

Country Link
US (1) US20140371094A1 (enExample)
EP (1) EP2776582A2 (enExample)
JP (2) JP6338530B2 (enExample)
KR (1) KR20140089384A (enExample)
CN (3) CN106011243A (enExample)
AR (1) AR088827A1 (enExample)
BR (1) BR112014011127A2 (enExample)
CA (1) CA2854779A1 (enExample)
HK (1) HK1214631A1 (enExample)
MX (1) MX2014005683A (enExample)
RU (1) RU2014123511A (enExample)
WO (1) WO2013071119A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753954A (zh) * 2018-06-26 2018-11-06 中南大学湘雅医院 痴呆相关基因的捕获探针组、试剂盒、文库构建方法和用途
CN117230184A (zh) * 2023-11-13 2023-12-15 深圳康美生物科技股份有限公司 基于飞行时间核酸质谱技术检测阿尔兹海默病基因的核酸组合及应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
EP2601609B1 (en) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
EP2766483B1 (en) 2011-10-10 2022-03-23 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2773779B1 (en) * 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
EP2900835B1 (en) 2012-09-27 2025-04-30 Population Bio, Inc. Method for screening and treating developmental disorders
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
WO2015082721A1 (en) * 2013-12-06 2015-06-11 Life & Brain Gmbh MEANS AND METHODS FOR ESTABLISHING A CLINICAL PROGNOSIS OF DISEASES ASSOCIATED WITH THE FORMATION OF AGGREGATES OF Aβ1-42
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
DK3201317T3 (da) * 2014-09-30 2020-01-20 Bgi Shenzhen Biomarkører for rheumatoid arthritis og anvendelse deraf
US11756655B2 (en) * 2015-10-09 2023-09-12 Guardant Health, Inc. Population based treatment recommender using cell free DNA
JP2017189121A (ja) * 2016-04-11 2017-10-19 国立大学法人旭川医科大学 抗ＴＮＦα抗体適応疾患の治療における抗ＴＮＦα抗体投与時反応の発症リスクを判定する方法、並びに該判定用オリゴヌクレオチドキット
KR102024862B1 (ko) * 2016-10-19 2019-09-25 삼성디스플레이 주식회사 표시 장치
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
WO2018212427A1 (ko) * 2017-05-15 2018-11-22 조선대학교산학협력단 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도
JP7112660B2 (ja) * 2018-03-13 2022-08-04 アイ２ディーエックス インコーポレイテッド 個別化医療における情報の電子配信
CA3108807A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
WO2020143044A1 (zh) * 2019-01-11 2020-07-16 深圳市双科生物科技有限公司 一种双质控检测方法
KR20200130165A (ko) * 2019-05-10 2020-11-18 주식회사 엠제이브레인바이오 Top3b 유전자 변이 기반 치매 진단방법
WO2021037027A1 (en) * 2019-08-29 2021-03-04 The Hong Kong University Of Science And Technology Genetic variants for diagnosis of alzheimer's disease
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
KR102561438B1 (ko) * 2020-11-04 2023-07-28 사회복지법인 삼성생명공익재단 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법
CN112980954B (zh) * 2021-03-03 2022-02-25 首都医科大学宣武医院 一种预测神经退行性疾病风险的试剂盒及其用途
EP4649090A1 (en) * 2023-01-09 2025-11-19 Eli Lilly And Company Anti-unc5c antibodies
WO2025125898A1 (en) * 2023-12-15 2025-06-19 Alchemab Therapeutics Ltd Anti-unc5c antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101812525A (zh) * 2010-04-09 2010-08-25 南通大学 与ad发病相关的基因网络通路分析模型的建立方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
PT2282779E (pt) * 2008-04-29 2013-05-28 Pharnext Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101812525A (zh) * 2010-04-09 2010-08-25 南通大学 与ad发病相关的基因网络通路分析模型的建立方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG ET AL: "Interleukin-6 receptor gene polymorphisms were associated with sporadic Alzheimer"s disease in Chinese Han", 《BRAIN RESEARCH》 *
马中华 等: "Nicastrin启动子区多态性与散发阿尔茨海默病相关性研究", 《中国神经精神疾病杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753954A (zh) * 2018-06-26 2018-11-06 中南大学湘雅医院 痴呆相关基因的捕获探针组、试剂盒、文库构建方法和用途
CN117230184A (zh) * 2023-11-13 2023-12-15 深圳康美生物科技股份有限公司 基于飞行时间核酸质谱技术检测阿尔兹海默病基因的核酸组合及应用
CN117230184B (zh) * 2023-11-13 2024-03-19 深圳康美生物科技股份有限公司 基于飞行时间核酸质谱技术检测阿尔兹海默病基因的核酸组合及应用

Also Published As

Publication number Publication date
JP2014533949A (ja) 2014-12-18
JP2018166507A (ja) 2018-11-01
KR20140089384A (ko) 2014-07-14
CA2854779A1 (en) 2013-05-16
WO2013071119A2 (en) 2013-05-16
CN106011243A (zh) 2016-10-12
US20140371094A1 (en) 2014-12-18
CN103930568A (zh) 2014-07-16
BR112014011127A2 (pt) 2017-05-16
JP6338530B2 (ja) 2018-06-06
MX2014005683A (es) 2015-01-22
AR088827A1 (es) 2014-07-10
WO2013071119A3 (en) 2013-07-11
RU2014123511A (ru) 2015-12-20
HK1214631A1 (zh) 2016-07-29
EP2776582A2 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
JP6338530B2 (ja) アルツハイマー病を治療、診断、および監視するための方法
Brouwers et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites
Ogino et al. Spinal muscular atrophy: molecular genetics and diagnostics
Hooli et al. Role of common and rare APP DNA sequence variants in Alzheimer disease
EP3202914B2 (en) Method for treating a neurodegenerative disease
JP5917460B2 (ja) アルツハイマー病の診断および治療
Hishimoto et al. Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease
Pastor et al. Further extension of the H1 haplotype associated with progressive supranuclear palsy
Fukusaki et al. Evidence for association between a Toll‐like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese population
JP2010506588A (ja) 肺の機能と障害の評価のための方法と組成物
US20120046341A1 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
JP2011505579A (ja) 眼圧を変調し、ステロイドの応答者と非応答者とを鑑別するための分子標的
Luedecking-Zimmer et al. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12
Paisán‐Ruiz et al. Homozygosity mapping through whole genome analysis identifies a COL18A1 mutation in an Indian family presenting with an autosomal recessive neurological disorder
JP2008509674A (ja) うつ病および不安についての処置応答を決定および予測するための組成物および方法
Chu et al. A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese
US20120208718A1 (en) Schizophrenia treatment response biomarkers
US20050255498A1 (en) APOC1 genetic markers associated with age of onset of Alzheimer's Disease
Chuang et al. Association of apolipoproteins e4 and c1 with onset age and memory: a study of sporadic Alzheimer disease in Taiwan
WO2011113004A2 (en) Markers associated with alzheimer's disease
EP2411541B1 (en) Markers related to age-related macular degeneration and uses therefor
EP2594649A1 (en) A method and a kit to predict response to antidepressant treatment
KR102650359B1 (ko) 약물 과민반응 진단용 snp 및 이를 이용한 진단 방법
HK1226781A (en) Methods for treating, diagnosing and monitoring alzheimer's disease
HK1226781A1 (en) Methods for treating, diagnosing and monitoring alzheimer's disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214631

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151118

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214631

Country of ref document: HK